Summary
Boston Scientific Corporation (BSX) has filed an 8-K report detailing the completion of its cash tender offer for various outstanding senior notes and the subsequent redemption of remaining eligible notes. The company successfully completed the tender offer on March 17, 2022, and has increased the aggregate maximum principal amount to be accepted to $2,852,561,000. This action is part of a larger set of "Transactions" that also include a new senior notes issuance and a redemption of specific notes not purchased in the tender offer. The overall impact of these transactions is expected to be accretive to adjusted earnings per share by approximately $0.02 in 2022. However, on a GAAP basis, the company anticipates a dilutive impact due to pre-tax debt extinguishment charges of approximately $200 million, primarily related to premiums paid in the tender offer, which will be recorded in the first quarter of 2022. Investors should note the distinction between GAAP and non-GAAP financial impacts.
Key Highlights
- 1Boston Scientific completed a cash tender offer for its outstanding senior notes on March 17, 2022, accepting a significant portion of the offered debt.
- 2The aggregate maximum principal amount of the tender offer was increased to $2,852,561,000.
- 3The company will redeem certain notes (2022, 2023, and 2025 notes) on March 31, 2022, to the extent they were not purchased in the tender offer.
- 4These tender offer and redemption activities, along with a recent debt issuance, are collectively referred to as 'Transactions'.
- 5The Transactions are expected to be accretive to adjusted earnings per share by approximately $0.02 in 2022.
- 6A pre-tax GAAP charge of approximately $200 million is anticipated in Q1 2022 due to debt extinguishment costs.
- 7The report incorporates press releases detailing the early results and pricing of the tender offer.